Masi M, De Vinci C, Baricordi O R
Department of Pediatrics, University of Bologna, Italy.
Biotherapy. 1996;9(1-3):97-103. doi: 10.1007/BF02628665.
Fifteen patients suffering from chronic mucocutaneous candidiasis were treated with an in vitro produced TF specific for Candida albicans antigens and/or with TF extracted from pooled buffy coats of blood donors. CMI of the patients was assessed using the LMT and the LST in presence of candidine. The aim of the study was the clinical evaluation of TF treatment and the incidence of positive tests before, during, and after therapy. Immunological data were matched using the Chi square test. 87 LMT were performed for each antigen dose and at the dilution of 1/50, 58.9% (33/56) tests were positive during non-treatment or non-specific TF treatment. On the contrary 83.9% (26/31) were positive during specific TF treatment (P < 0.05). In the LST, a significant decrease of thymidine uptake in the control cultures in presence of autologous or AB serum was observed when patients were matched according to non-treatment, and both non specific (P < 0.05) and specific TF treatment (P < 0.01). Only during specific TF treatment was a significant increase of reactivity against the Candida antigen at the highest concentration noticed, when compared with the period of non specific treatment (P < 0.01). Clinical observations were encouraging: all but one patient experienced significant improvement during treatment with specific TF. These data confirm that orally administered specific TF, extracted from induced lymphoblastoid cell-lines, increases the incidence of reactivity against Candida antigens in the LMT. LST reactivity appeared not significantly increased with respect to the periods of non treatment, but was significantly increased when it was compared to the non-specific TF treatment periods. At the same time, a clinical improvement was noticed.
15名慢性黏膜皮肤念珠菌病患者接受了针对白色念珠菌抗原的体外制备转移因子（TF）和/或从献血者汇集的血沉棕黄层中提取的TF治疗。使用淋巴细胞转化试验（LMT）和在念珠菌素存在下的淋巴细胞刺激试验（LST）评估患者的细胞介导免疫（CMI）。该研究的目的是对TF治疗进行临床评估以及观察治疗前、治疗期间和治疗后阳性试验的发生率。使用卡方检验对免疫数据进行匹配。每种抗原剂量在1/50稀释度下进行了87次LMT，在未治疗或非特异性TF治疗期间，58.9%（33/56）的试验呈阳性。相反，在特异性TF治疗期间，83.9%（26/31）的试验呈阳性（P<0.05）。在LST中，当根据未治疗、非特异性（P<0.05）和特异性TF治疗（P<0.01）对患者进行匹配时，在存在自体或AB血清的对照培养物中观察到胸苷摄取显著降低。仅在特异性TF治疗期间，与非特异性治疗期相比，在最高浓度下观察到对念珠菌抗原的反应性显著增加（P<0.01）。临床观察结果令人鼓舞：除一名患者外，所有患者在接受特异性TF治疗期间均有显著改善。这些数据证实，口服从诱导淋巴母细胞系中提取的特异性TF可增加LMT中针对念珠菌抗原的反应性发生率。与未治疗期相比，LST反应性似乎没有显著增加，但与非特异性TF治疗期相比显著增加。同时，观察到临床改善。
